AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment of the signs of inflammation associated with allergic conjunctivitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Collaborator: Ophthalmic Research Associates, Inc.
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Presence of signs and symptoms of ocular inflammation in both eyes.

• Have a positive CAC response at Visit 1.

• Able to avoid the use of disallowed medications as well as contact lens wear for the specified period prior to Visit 1, and for the duration of the study.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Have known history or presence of persistent dry eye syndrome.

• Presence of any ophthalmic abnormality that may affect the study outcomes.

• Have a history of moderate to severe allergic asthma reaction to mountain cedar or the perennial allergens used in the study.

• Other protocol-defined exclusion criteria may apply.